Cantor Fitzgerald Has Weak Estimate for TNGX FY2025 Earnings

Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Equities researchers at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for shares of Tango Therapeutics in a research report issued to clients and investors on Monday, March 10th. Cantor Fitzgerald analyst E. Schmidt now forecasts that the company will post earnings of ($1.48) per share for the year, down from their previous forecast of ($1.39). Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Tango Therapeutics' current full-year earnings is ($1.19) per share.

Tango Therapeutics Stock Down 0.5 %

Shares of TNGX stock opened at $1.85 on Wednesday. The firm has a market capitalization of $200.00 million, a P/E ratio of -1.57 and a beta of 0.87. Tango Therapeutics has a twelve month low of $1.72 and a twelve month high of $12.02. The stock's fifty day simple moving average is $2.70 and its 200 day simple moving average is $4.86.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.03). Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%. The business had revenue of $4.12 million for the quarter, compared to analyst estimates of $7.84 million.

Institutional Investors Weigh In On Tango Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in TNGX. Dynamic Technology Lab Private Ltd acquired a new position in Tango Therapeutics during the 4th quarter worth approximately $33,000. Stonebrook Private Inc. purchased a new stake in shares of Tango Therapeutics in the fourth quarter worth approximately $34,000. Ameriprise Financial Inc. purchased a new stake in shares of Tango Therapeutics in the fourth quarter worth approximately $35,000. Sherbrooke Park Advisers LLC purchased a new stake in shares of Tango Therapeutics in the fourth quarter worth approximately $38,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Tango Therapeutics in the fourth quarter worth approximately $40,000. Institutional investors own 78.99% of the company's stock.

Insider Buying and Selling

In related news, CEO Barbara Weber sold 9,778 shares of the business's stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $2.99, for a total transaction of $29,236.22. Following the sale, the chief executive officer now owns 1,631,264 shares in the company, valued at $4,877,479.36. The trade was a 0.60 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders have sold 24,268 shares of company stock worth $72,561 in the last 90 days. Insiders own 6.30% of the company's stock.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Remove Ads